Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

clinical investigation of the TLR7 mechanism in HCV by taking ANA773 into a clinical trial under a two-part protocol designed to test ANA773 in both healthy volunteers and patients with HCV. In October, Anadys completed dosing in healthy volunteers. Subjects received a single dose followed by four doses taken every other day, at levels from 200 mg to 1600 mg (with six subjects receiving active and two receiving placebo in each dose cohort). No serious adverse events were reported. Biomarker induction indicative of immune activation was seen in a majority of subjects beginning at 800 mg. Some side effects commonly seen with interferon treatment, including fever and chills, were observed at higher doses, with the frequency and intensity of interferon-like side effects increasing with dose. One subject at the 1200 mg dose and two subjects at the 1600 mg dose discontinued from the trial before completion of dosing. Anadys expects to initiate Part B of the study in HCV patients within the next few weeks. Patients in the first cohort will receive 800 mg of ANA773 every other day for 28 days. Doses for subsequent cohorts will be selected based on viral load and tolerability data from the 800 mg cohort.

-- Phase I Clinical Trial of ANA773 in Oncology. Anadys continues to enroll patients in an ongoing Phase I clinical trial of ANA773 in oncology and has now completed enrollment in the third cohort.

Webcast of Conference Call

Anadys will host a conference call at 5:00 p.m. EDT today to discuss its third quarter financial results and highlights and to provide an update on its development programs. A live webcast of the call will be available online at http://www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 86226986. The webcast and t
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 2015  In response to the incorrect assertions by ... on February 12, 2015. Impeto Medical SAS ... health and their SUDOSCAN® devices have been proven to ... prefers to have the courts decide this dispute rather ... 40 articles written by Key Opinion Leaders, published by ...
(Date:3/4/2015)... Nev. , March 4, 2015 PDL BioPharma, Inc. ... adjusted conversion rate for the: , 3.75% Convertible ... 174.8506 shares of common stock per $1,000 principal amount or ... The conversion rate for the note is adjusted in connection ... on March 12, 2015, to all stockholders who own shares of ...
(Date:3/4/2015)... USDM Life Sciences , a leading ... hired David Blewitt as Vice President of ... and Solutions at USDM Life Sciences , which help ... compliance with government regulations worldwide. , For more ... sciences regulatory and IS compliance professional with extensive hands-on ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 PRC ... in the San Francisco Bay Area, will exhibit and ... Israel Conference 2015 on March 25th and 26th ... to build relationships with Israeli life science companies seeking ... trials. The company’s services span all phases of human ...
Breaking Biology Technology:Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4
... Focus on ... Supportive ... Companies, Inc. (NYSE: PRX ) today announced its commitment,to ... of Strativa Pharmaceuticals, its proprietary,specialty pharmaceuticals division. Strativa Pharmaceuticals will ...
... Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ), a ... of drugs for the treatment of human ... part of the,restructuring, Idenix has amended the ... Tyzeka(R)/Sebivo(R). Per the amended agreement, Idenix,will discontinue ...
... Settlement, NORCROSS, Ga., Sept. 28 ... leader in providing automated instrument-reagent,systems to the ... and Exchange Commission (SEC) has agreed to ... certain,activities involving the company,s Italian subsidiary. ...
Cached Biology Technology:Introducing Strativa Pharmaceuticals 2Introducing Strativa Pharmaceuticals 3Introducing Strativa Pharmaceuticals 4Introducing Strativa Pharmaceuticals 5Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs 2Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs 3Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs 4Immucor Settles SEC Investigation 2
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62114357 for DISTRIBUTED VOICE DIRECTED ... NXT-ID introduces a new groundbreaking payment method. Payment accounts ... account may only be accessed if both the speech ...
(Date:2/18/2015)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. , Cowen and Company Health ... 3, 2015 at 11.20 a.m. Eastern Time , Raymond ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... these events, please visit Cepheid,s website at http://ir.cepheid.com ...
(Date:2/12/2015)... , Feb. 12, 2015   MedNet ... specializing in clinical study management systems, has recently ... , further distinguishing iMedNet ... Research Organizations (CROs) and healthcare consultants.  Building on ... prospective customer referrals and numerous co-marketing opportunities), MedNet,s ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... one day in the distant future, miniature, medically-savvy computers ... them on the spot by releasing a suitable drug, ... reality, computers must be sufficiently small to fit into ... to various cellular systems. These challenges can be best ...
... HOLE, MASS. -- Among the animals that are appealing ... to mind. Slender, limbless, primitive blobs that look pretty ... boring. I wouldn,t recommend them for a home aquarium," ... Biological Laboratory (MBL). Yet Nasi and his collaborators managed ...
... Darwin on the Galapagos Islands, researchers have been interested ... particular island, can lead to the formation of new ... selection is a process whereby heritable traits that enhance ... heritable traits become less common. Over time, animals and ...
Cached Biology News:A genetic device performs DNA diagnosis 2Sensing the light, but not to see 2LSU professor discovers how new corals species form in the ocean 2LSU professor discovers how new corals species form in the ocean 3
... of a series of media originally developed at ... al. for the large scale propagation of cells ... primarily used for the growth and maintenance of ... of viruses in these cell lines. One of ...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Mfr ...
Biology Products: